YouTube

Pediatime Logo

YouTube: Subscribe to Pediatime!

Stay updated with the latest pediatric education videos.

Subscribe Now

Landau-Kleffner Syndrome

Landau-Kleffner Syndrome (LKS)

Landau-Kleffner syndrome (LKS), also known as acquired epileptic aphasia, is a rare childhood neurological disorder characterized by the sudden or gradual development of aphasia (language disorder) and an abnormal electroencephalogram (EEG).

Key Points:

  • Age of onset: Typically between 3-7 years
  • Gender distribution: Affects both males and females equally
  • Prevalence: Rare disorder, exact incidence unknown
  • First described by William Landau and Frank Kleffner in 1957

Clinical Manifestations

Language Dysfunction

  • Acquired aphasia
    • Progressive loss of receptive language
    • Verbal auditory agnosia
    • Expressive language deterioration
  • Language regression pattern
    • Initially normal language development
    • Sudden or gradual loss of language abilities
    • May progress to complete mutism

Seizure Activity

  • Occurs in 70-80% of cases
  • Types:
    • Focal seizures
    • Generalized tonic-clonic seizures
    • Atypical absence seizures
  • Predominantly nocturnal seizures

Behavioral Changes

  • Hyperactivity
  • Attention deficits
  • Aggression
  • Social withdrawal
  • Emotional lability

Diagnostic Criteria and Workup

EEG Findings

  • Characteristic spike-wave discharges
    • Bilateral temporal regions
    • Activation during sleep
    • Continuous spike-waves during slow-wave sleep (CSWS)

Required Investigations

  • Serial EEG recordings (awake and sleep)
  • Brain MRI
  • Comprehensive neuropsychological assessment
  • Audiological evaluation
  • Speech and language assessment

Differential Diagnosis

  • Autism spectrum disorders
  • Childhood disintegrative disorder
  • Hearing impairment
  • Other epileptic encephalopathies
  • CSWS syndrome

Treatment Approaches

Antiepileptic Medications

  • First-line options:
    • Valproic acid
    • Levetiracetam
    • Clobazam
  • Second-line options:
    • Ethosuximide
    • Sulthiame

Immunomodulatory Therapy

  • Corticosteroids
    • Oral prednisolone
    • ACTH
    • Pulse methylprednisolone
  • Intravenous immunoglobulins (IVIG)

Rehabilitation Services

  • Speech and language therapy
  • Occupational therapy
  • Educational support
  • Behavioral intervention
  • Family counseling

Outcome and Follow-up

Prognostic Factors

  • Favorable factors:
    • Early diagnosis and treatment
    • Later age of onset
    • Shorter duration of active phase
  • Poor prognostic factors:
    • Early age of onset
    • Prolonged CSWS
    • Delayed treatment initiation

Long-term Outcomes

  • Language recovery:
    • Variable recovery patterns
    • 20-30% complete recovery
    • 40-50% partial recovery
    • 20-30% persistent deficits
  • Seizure outcomes:
    • Generally good seizure control
    • Most patients seizure-free by adolescence
Further Reading


Powered by Blogger.